Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia - Full Text View

Purpose

RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia.

PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.

Condition	Intervention	Phase
Fanconi Anemia	Biological: anti-thymocyte globulin Biological: filgrastim Drug: busulfan Drug: cyclophosphamide Drug: fludarabine phosphate Drug: methylprednisolone Biological: Hematopoietic stem cell transplantation	Phase 2


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02

Resource links provided by NLM:

Genetics Home Reference related topics: Fanconi anemia

MedlinePlus related topics: Anemia

Genetic and Rare Diseases Information Center resources: Fanconi Anemia Congenital Aplastic Anemia Fanconi Syndrome Nephropathic Cystinosis Primary Fanconi Syndrome

U.S. FDA Resources

Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:

Percent of Graft Failure [ Time Frame: Day 30 ]
Graft failure = ANC <5 x 10^8/L by day 30.

Secondary Outcome Measures:

Incidence of Acute and Chronic Graft-Versus-Host Disease [ Time Frame: Day 42 and 1 Year ]
Incidence of Relapse [ Time Frame: 1 Year ]
Incidence of Major Infections [ Time Frame: Day 1 through End of Treatment ]
Transplant-Related Toxicity [ Time Frame: Day 100 ]
Overall Survival [ Time Frame: 1 Year ]
cumulative proportion surviving
Incidence of Chronic Graft-Versus-Host Disease [ Time Frame: Day 42 and 1 Year ]


Estimated Enrollment:	25
Actual Study Start Date:	March 26, 2002
Estimated Study Completion Date:	January 2019
Estimated Primary Completion Date:	January 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: transplant in fanconi anemia patients Cytoreductive preparative regimen consisting of busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, and antithymocyte globulin (ATG) followed by hematopoietic stem cell transplantation (HSCT) and post-transplant use of bone marrow-stimulating filgrastim.	Biological: anti-thymocyte globulin Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1. Other Name: ATG Biological: filgrastim given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L) Other Name: G-CSF Drug: busulfan Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old) Other Name: Busulfex Drug: cyclophosphamide 10 mg/kg intravenously (IV) on Days -5 through -2. Other Name: Cytoxan Drug: fludarabine phosphate 35 mg/m^2 intravenously (IV) on Days -5 through -2. Other Name: Fludara Drug: methylprednisolone 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1. Other Name: Medrol Biological: Hematopoietic stem cell transplantation Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program. Other Name: HSCT

Arms

Assigned Interventions

Experimental: transplant in fanconi anemia patients

Cytoreductive preparative regimen consisting of busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, and antithymocyte globulin (ATG) followed by hematopoietic stem cell transplantation (HSCT) and post-transplant use of bone marrow-stimulating filgrastim.

Biological: anti-thymocyte globulin

Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.

Other Name: ATG

Biological: filgrastim

given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L)

Other Name: G-CSF

Drug: busulfan

Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old)

Other Name: Busulfex

Drug: cyclophosphamide

10 mg/kg intravenously (IV) on Days -5 through -2.

Other Name: Cytoxan

Drug: fludarabine phosphate

35 mg/m^2 intravenously (IV) on Days -5 through -2.

Other Name: Fludara

Drug: methylprednisolone

1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.

Other Name: Medrol

Biological: Hematopoietic stem cell transplantation

Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.

Other Name: HSCT

Detailed Description:

OBJECTIVES:

Primary

Determine whether the incidence of neutrophil engraftment is acceptable in high-risk patients with Fanconi's anemia treated with busulfan, cyclophosphamide, fludarabine, and antithymocyte globulin followed by allogeneic hematopoietic stem cell transplantation.

Secondary

Determine the tolerability of mycophenolate mofetil in these patients.
Determine the incidence of acute and chronic graft-vs-host disease in patients treated with this regimen.
Determine the incidence of major infections in patients with a history of major infections treated with this regimen.
Determine the incidence of relapse in patients with refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia treated with this regimen
Determine the probability of 1-year survival of patients treated with this regimen.

OUTLINE: Patients are stratified according to donor/recipient HLA type (identical vs other).

Cytoreductive combination chemotherapy: Patients receive busulfan intravenously (IV) over 2 hours twice daily on days -7 and -6 and cyclophosphamide IV over 2 hours and fludarabine IV over 30 minutes once daily on days -5 to -2.
Graft failure prophylaxis: Patients receive methylprednisolone IV twice daily on days -5 to 30 and anti-thymocyte globulin IV over 4-6 hours twice daily on days -5 to -1.
Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours twice daily on days -3 to 100 (if patient has a matched sibling donor) or days -3 to 180 (if patient has another donor type). Patients also receive mycophenolate mofetil orally or IV twice daily on days -3 to 45.
Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic HSCT (using bone marrow or umbilical cord blood) on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.

After completion of study treatment, patients are followed periodically for 3 years.

Eligibility


Ages Eligible for Study:	up to 44 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must be <45 years of age with a diagnosis of Fanconi anemia with:
- Biallelic BRCA2 mutations, or
- Aplastic anemia, or advanced myelodysplastic syndrome (MDS) (MDS with ≥5% blasts), or acute leukemia who are ineligible for total body irradiation. Aplastic anemia is defined as having at least one of the following (with or without cytogenetic abnormalities): platelet count <20 * 10^9, - absolute neutrophil count (ANC) <5 * 10^8/L, - Hgb <8 g/dL /
Patients must have an HLA-A, B, DRB1 identical or 1 antigen mismatched related or unrelated BM donor or have an HLA-A, B, DRB1 identical, 1 antigen or 2 antigen mismatched related or unrelated umbilical cord blood (UCB) donor. Patients and donors will be typed for HLA-A and B using serological level typing and for DRB1 using high resolution molecular typing.
Adequate major organ function including:
- Cardiac: ejection fraction >45%
- Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites, no cirrhosis)
- Karnofsky performance status >70% or Lansky >50%
Women of child bearing potential must be using adequate birth control and have a negative pregnancy test.

Exclusion Criteria:

Active CNS leukemia at time of HSCT.
Active uncontrolled infection within one week of hematopoietic stem cell transplant (HSCT).
Pregnant or lactating female.

Donor Inclusion Criteria:

Donor must be in good health based on review of systems and results of physical examination.
Donor must have a normal hemoglobin, white count, platelet count and partial thromboplastin time (PTT), and a negative diepoxybutane (DEB) test.
HIV-NAT negative, HTLV-1, HTLV-2 negative, Hepatitis B and C negative.
Female donors of childbearing potential must have a negative pregnancy test.
Unrelated donors must agree to peripheral blood stem cell (PBSC) donation

Donor Exclusion Criteria:

Donor is a lactating female.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00258427

Contacts


Contact: Timothy Krepski	612-273-2800	tkrepsk1@fairview.org

Locations


United States, Minnesota
Masonic Cancer Center, University of Minnesota	Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Timothy Krepski 612-273-2800 tkrepsk1@fairview.org
Principal Investigator: Margaret MacMillan, M.D.

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota

Investigators


Principal Investigator:	Margaret MacMillan, MD	Masonic Cancer Center, University of Minnesota

More Information


Responsible Party:	Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:	NCT00258427 History of Changes
Other Study ID Numbers:	2002LS014 MT2002-02 ( Other Identifier: Blood and Marrow Transplantation Program ) 0202M18741 ( Other Identifier: IRB, University of Minnesota )
Study First Received:	November 22, 2005
Last Updated:	February 17, 2017

Keywords provided by Masonic Cancer Center, University of Minnesota:


Fanconi anemia

Additional relevant MeSH terms:


Anemia Fanconi Anemia Fanconi Syndrome Hematologic Diseases Anemia, Hypoplastic, Congenital Anemia, Aplastic Bone Marrow Diseases Genetic Diseases, Inborn DNA Repair-Deficiency Disorders Metabolic Diseases Renal Tubular Transport, Inborn Errors Kidney Diseases Urologic Diseases Metabolism, Inborn Errors Fludarabine	Fludarabine phosphate Cyclophosphamide Methylprednisolone Hemisuccinate Prednisolone Busulfan Antilymphocyte Serum Vidarabine Lenograstim Prednisolone acetate Methylprednisolone acetate Methylprednisolone Prednisolone hemisuccinate Prednisolone phosphate Antineoplastic Agents Antimetabolites, Antineoplastic

ClinicalTrials.gov processed this record on June 27, 2017